Molecular Partners AG’s MOLN share price has surged by 9.28%, which has investors questioning if this is right time to sell.

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, March 27, 2025 - Santhera Pharmaceuticals (SIX: SANN) proposes to elect Dr. Melanie Rolli as an Independent Director at the upcoming A ...

The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...

We are delighted to welcome Stephen to TScan at this stage of growth for the Company,” said Gavin MacBeath, Ph.D., Chief Executive Officer. “His robust commercial leadership experience includes over ...

The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...

Neoplastic Agents Market Report 2025" has been added to ResearchAndMarkets.com's offering.This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, ...

The Wasatch Global Value Fund—Investor Class returned -5.78% in the fourth quarter of 2024, underperforming the MSCI AC (All Country) World Value Index, which lost -4.71%.

More and more people are talking about Novartis over the last few weeks. Is it worth buying the Pharmaceutical stock at a price of $112.13? Only time will tell. The information below will give you a ...